Ian MacLachlan

Summary

Affiliation: Boston University
Country: USA

Publications

  1. pmc Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA, USA
    Vaccine 26:6894-900. 2008
  2. pmc Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
  3. pmc Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    PLoS Pathog 4:e1000225. 2008
  4. pmc Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
  5. doi request reprint Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA 02118, USA
    Lancet 375:1896-905. 2010
  6. pmc Postexposure treatment of Marburg virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts 02118, USA
    Emerg Infect Dis 16:1119-22. 2010

Detail Information

Publications6

  1. pmc Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA, USA
    Vaccine 26:6894-900. 2008
    ..Interestingly, disease in control animals appeared to progress slower than previously seen in macaques exposed to comparable doses by intramuscular injection...
  2. pmc Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    J Virol 82:5664-8. 2008
    ..This is the first demonstration of complete postexposure protection against an Ebola virus in nonhuman primates and provides further evidence that postexposure vaccination may have utility in treating exposures to filoviruses...
  3. pmc Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, USA
    PLoS Pathog 4:e1000225. 2008
    ..Evaluation of CD4+ T cells in all animals showed that the animals that succumbed to lethal ZEBOV challenge had the lowest CD4+ counts, suggesting that CD4+ T cells may play a role in mediating protection against ZEBOV...
  4. pmc Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus
    Thomas W Geisbert
    Department of Microbiology, National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Virol 83:7296-304. 2009
    ..In conclusion, we developed an immunization scheme based on a single-injection vaccine that protects nonhuman primates against lethal challenge with representative strains of all human pathogenic filovirus species...
  5. doi request reprint Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston University School of Medicine, Boston, MA 02118, USA
    Lancet 375:1896-905. 2010
    ..We therefore assessed the efficacy of modified non-immunostimulatory siRNAs in a uniformly lethal non-human primate model of ZEBOV haemorrhagic fever...
  6. pmc Postexposure treatment of Marburg virus infection
    Thomas W Geisbert
    National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts 02118, USA
    Emerg Infect Dis 16:1119-22. 2010
    ..We protected 5/6 monkeys when this vaccine was given 24 h after challenge; 2/6 animals were protected when the vaccine was administered 48 h postinfection...

Research Grants1